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What’s new? 
• KCNJ11 mutations causing permanent neonatal diabetes are treated with 
sulfonylureas, but not all individuals are able to transfer completely from insulin to 
sulfonylureas. 
• Our data highlight that combining sulfonylurea treatment with insulin in those who 
are unable to fully transfer may still lead to clinically meaningful outcomes. 
• We demonstrate improvements in endogenous insulin production, HbA1c, glycaemic 
variability and hypoglycaemia awareness. 
• These changes were not observed at initial doses of glibenclamide and improvements 
required higher sustained doses of glibenclamide. 
• Combining insulin and sulfonylureas should be considered in those with permanent 
neonatal diabetes who are not able to transfer to sulfonylurea therapy alone. 
 
Abstract 
Background Permanent neonatal diabetes caused by mutations in the KCNJ11 gene may be 
managed with high-dose sulfonylureas. Complete transfer to sulfonylureas is not successful 
in all cases and can result in insulin monotherapy. In such cases, the outcomes of combining 
sulfonylureas with insulin have not been fully explored. We present the case of a woman with 
diabetes due to a KCNJ11 mutation, in whom combination therapy led to clinically 
meaningful improvements. 
Case A 22-year-old woman was found to have a KCNJ11 mutation (G334V) following 
diagnosis with diabetes at 3 weeks. She was treated with insulin-pump therapy, had 
hypoglycaemia unawareness and suboptimal glycaemic control. We assessed the in vitro 
response of the mutant channel to tolbutamide in Xenopus oocytes and undertook 
sulfonylurea dose-titration with C-peptide assessment and continuous glucose monitoring. 
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In vitro studies predicted the G334V mutation would be sensitive to sulfonylurea therapy 
[91 ± 2% block (n = 6) with 0.5 mM tolbutamide]. C-peptide increased following a 
glibenclamide test dose (from 5 to 410 pmol/l). Glibenclamide dose-titration was undertaken: 
a lower glibenclamide dose did not reduce blood glucose levels, but at 1.2 mg/kg/day insulin 
delivery was reduced to 0.1 units/h. However, when insulin was stopped, hyperglycaemia 
ensued. Glibenclamide was further increased (2 mg/kg/day), but once-daily long-acting 
insulin was still required to maintain glycaemia. This resulted in improved HbA1c of 
52 mmol/mol (6.9%), restoration of hypoglycaemia awareness and reduced glycaemic 
variability. 
Conclusion In people with KCNJ11 mutations causing permanent neonatal diabetes, and 
where complete transfer is not possible, consideration should be given to dual insulin and 
sulfonylurea therapy. 
 
<H1>Introduction 
Permanent neonatal diabetes mellitus is a rare monogenic form of diabetes that presents 
within the first 6 months of life [1]. Mutations in the KCNJ11 and ABCC8 genes, encoding 
the Kir6.2 and SUR1 subunits, respectively, of the pancreatic β-cell ATP-sensitive potassium 
channel (KATP channel) account for 50% of cases [2,3]. The KATP channel plays a key role in 
insulin secretion by regulating the β-cell plasma membrane potential, and thereby insulin 
secretion, in response to the ambient glucose concentration [4]. At low glucose levels, the 
channel is open, keeping the membrane hyperpolarized and inhibiting insulin release. 
However, when glucose levels rise, the accompanying increase in metabolically generated 
ATP closes the KATP channel, resulting in membrane depolarization and activation of 
voltage-gated calcium entry, which stimulates insulin secretion. Activating mutations in 
either KCNJ11 or ABCC8 impair the ability of the channel to respond to ATP and as a 
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consequence, the KATP channel remains open despite of elevated plasma glucose. This 
impairs insulin release and results in diabetes. 
Sulfonylurea drugs bind to the SUR1 subunit of the KATP channel and close it independently 
of ATP, thereby stimulating insulin release. They are now the therapy of choice in children 
with permanent neonatal diabetes caused by mutations in KCNJ11 or ABCC8 [5]. Prior to the 
discovery of the genetic cause of permanent neonatal diabetes, people with the condition 
were treated with insulin. However, ~ 90% of people with neonatal diabetes due to a KCNJ11 
mutation have been able to successfully transfer from insulin to high-dose oral sulfonylurea 
therapy, which usually results in significant improvements in HbA1c [5–7]. 
Unsuccessful transfer is determined by two factors: the sensitivity of the mutant KATP channel 
to sulfonylurea inhibition, and the duration of diabetes prior to transfer [6,7]. Some mutant 
channels are less sensitive to sulfonylurea inhibition, and no cases with a mutation that shows 
< 60% block of the KATP current by 0.5 mM tolbutamide in in vitro studies, have been able to 
transfer. In other cases, however, where some people have been able to transfer but others 
with the same mutation have been unable to do so, the ability to transfer is correlated with the 
duration of diabetes; an earlier age at transfer is more likely to result in success [6,7]. 
In those who have been unable to transfer completely to sulfonylureas, variable practice is 
observed with some reverting to insulin monotherapy, and others remaining on a combination 
of sulfonylureas and insulin or other agents [6–8]. The clinical benefits of remaining on 
combined insulin and sulfonylurea therapy have not been fully explored. 
We report a case in which sulfonylurea therapy in combination with insulin treatment enabled 
a significant reduction in insulin dose, transition off insulin pump therapy and led to 
clinically meaningful improvements in HbA1c, glycaemic variability and hypoglycaemia 
awareness. We undertook clinical and in vitro studies to investigate this phenotype further 
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and show that the inability to transfer off insulin completely should not be considered a 
failure if the addition of sulfonylureas to the treatment regime results in improved glycaemia. 
<H1>Methods 
<H2>Molecular genetics 
Genomic DNA was extracted from peripheral leukocytes using standard procedures. The 
coding regions and conserved splice sites of the ABCC8 and KCNJ11 genes were amplified 
by polymerase chain reaction (PCR) and the resulting amplicons sequenced using the Big 
Dye Terminator Cycler Sequencing Kit v3.1 (Applied Biosystems, Warrington, UK). The 
products were analysed on an ABI 3730 capillary sequencer (Applied Biosystems) and 
compared to the reference sequences (NM_000525.3 and NM_000352.3) using Mutation 
Surveyor v3.24 software (SoftGenetics, State College, PA, USA). 
<H2>Functional studies 
We used human Kir6.2 (GenBank NM000525, with E23 and I337) and rat SUR1 (GenBank 
L40624). Site-directed mutagenesis of Kir6.2 was performed as described previously [6,9]. 
Defolliculated Xenopus laevis oocytes were injected with 0.8 ng wild-type (or mutant) Kir6.2 
mRNA and 4 ng SUR1 mRNA, and were incubated in Barth’s solution at 18 °C for 1–4 days. 
To simulate the heterozygous state of the heterozygous phenotype, we co-injected a 1 : 1 
mixture of mutant and wild-type Kir6.2, together with SUR1. The resulting channel 
population (referred to here as hetG334V) contains a variable number of mutant subunits 
(between zero and four) in the Kir6.2 tetramer. 
<H2>Clinical investigations 
All studies were undertaken on the clinical investigation unit. Sulfonylurea test dose and oral 
glucose tolerance tests were undertaken according to the Exeter team protocol [10]. Briefly, 
following cessation of bolus insulin and a 75-g oral glucose tolerance test, a test dose of 
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~ 0.1 mg/kg of glibenclamide was administered. Subsequent dose titration was carried out 
according to the transfer protocol. 
<H1>Results 
<H2>Clinical data 
A 22-year-old woman of South East Asian ethnicity was diagnosed with diabetes at the age 
of 3 weeks in her home country. This was assumed to be Type 1 diabetes. She was delivered 
following a caesarean section (breech position) at term weighing 3.2 kg. She developed 
normally during childhood with no delay in achieving milestones, no epilepsy and only a 
diagnosis of mild dyslexia. She was treated for 17 years with multiple daily injections of 
insulin, before commencing insulin pump therapy at the age of 18 years. She had several 
documented episodes of diabetic ketoacidosis during her childhood and teenage years. 
Neither of her parents or her only sibling was affected with diabetes. 
<H2>Genetic data 
Having moved to the UK, genetic testing for permanent neonatal diabetes was requested on 
the basis of her diagnosis before 6 months of age. Genetic testing revealed a heterozygous 
KCNJ11 missense mutation, p.G334V (c.1001G > T), presumed to have occurred de novo, 
given absence of diabetes in either parent. 
At the time of genetic testing, the woman had an above target HbA1c of 88 mmol/mol, 
impaired awareness of hypoglycaemia, background retinopathy and significant abdominal 
lipohypertrophy (see Table 1 for baseline characteristics). There was no evidence of 
nephropathy or neuropathy. She required between 80 and 85 units of insulin per day via a 
pump, delivered with variable basal rates and bolus mealtime insulin. Continuous glucose 
monitoring (CGM) was undertaken in view of her frequent hypoglycaemia and revealed 
significant glycaemic variability (SD 4.0 mmol/l) with hyperglycaemic excursions and 
frequent hypoglycaemia. 
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Functional studies (see below) were undertaken to determine if the Kir6.2-G334V mutant 
channels were sensitive to sulfonylurea inhibition, with positive results. Consequently, a 
glibenclamide test dose was undertaken following a day admission, as part of clinical care 
(see Fig. 1). This revealed an immediate and significant rise in C-peptide following a 5 mg 
glibenclamide test dose, indicating that the β cells were capable of releasing endogenous 
insulin. A formal glibenclamide trial was therefore undertaken using the Exeter protocol [10] 
(see Fig. 2 for a summary of the dose titration), and insulin basal rates were reduced in 
parallel with increasing glibenclamide doses. 
Within 8 weeks of commencing treatment, she was receiving a glibenclamide dose of 20 mg 
twice daily (0.67 mg/kg/day; 40 mg/day total) and her basal insulin (insulin glargine, Lantus) 
requirements had reduced to a total basal dose of 9.6 units/day via her insulin pump 
(0.4 units/h). Her median blood glucose, as assessed by frequent home blood glucose 
monitoring, was 8.4 mmol/l. Basal insulin was further reduced, but glucose levels rose to a 
median of 12 mmol/l. Glibenclamide was therefore increased to a dose of 70 mg/day 
(1.2 mg/kg/day in three divided doses of 30, 10 and 30 mg) and basal insulin was reduced to 
0.1 units/h (total basal dose 2.4 units/day). At this point, her median blood glucose was 
8.6 mmol/l and an attempt to stop insulin completely was undertaken. However, following 
disconnection of the pump, glucose levels rapidly rose to between 20 and 25 mmol/l within 
6 h (capillary blood ketones were 0.4 mmol/l), insulin was therefore recommenced the 
following day. 
Following discussion, a higher dose of glibenclamide was given (40 mg three times daily; 
2 mg/kg/day) for several months, however, insulin was still required to maintain 
normoglycaemia. This was achieved through once-daily injections of long-acting insulin, 
enabling discontinuation of pump therapy. After commencement of glibenclamide, her HbA1c 
fell to 52 mmol/mol (6.9%) and her random C-peptide was 637 pmol/l (Table 1). Her 
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hypoglycaemia awareness was also restored. Repeat CGM revealed some hypoglycaemia and 
her glargine dose was reduced accordingly. The standard deviation (SD) of blood glucose 
measurements was significantly lower (at 2.7 mmol/l) than before sulfonylurea therapy. She 
is currently maintained on 40 mg glibenclamide three times daily and 10 units insulin 
glargine once daily, with no mealtime insulin bolus. 
 <H2>Functional studies 
The latest crystal structure reveals that residue G334 forms part of the ATP-binding site and 
may reduce the ability of ATP to bind to Kir6.2, either by steric interference or electrostatic 
repulsion [11]. We therefore first examined the sensitivity of wild-type (WT) and mutant 
channels to inhibition by MgATP. Figure S1 shows that WT channels were half maximally 
blocked (IC50) by 20 ± 1 µM MgATP (n = 7). The ATP sensitivity of heterozygous 
(hetG334V) Kir6.2-G334V/SUR1 channels was significantly decreased (IC50 = 163 ± 42 µM, 
n = 6; P < 0.01 vs. WT) and that of homozygous (homG334V) channels was reduced even 
further (IC50 = 2.6 ± 0.5 mM, n = 3). There was also a substantial increase in the current 
amplitude at physiological levels of MgATP: at 3 mM, the percentage of unblocked current 
was 1.2 ± 0.2% (n = 7) for WT, whereas it was 12 ± 2% (n = 6) and 48 ± 4% (n = 3) for 
hetG334V and homG334V, respectively. This increase in current can account for the diabetes 
in the presented case and demonstrates that the mutation is pathological. 
We next analysed the effects of the Kir6.2-G334V mutation on the metabolic regulation and 
sulfonylurea sensitivity of the KATP channel by measuring whole-cell currents. When WT 
KATP channels are expressed in Xenopus oocytes they are normally closed, due to the high 
intracellular ATP concentration ([ATP]i). However, they can be opened by lowering [ATP]i 
using a metabolic inhibitor such as Na-azide (Fig. 3a). Mutations that reduce the channel 
ATP sensitivity normally increase the whole-cell current in control solution, reflecting the 
fact that they are less blocked by resting [ATP]i. Both hetG334V and homG334V currents 
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were substantially larger than WT both in control solution (Fig. 3a), as expected from their 
lower ATP sensitivity. The sulfonylurea tolbutamide, at a dose that maximally inhibits the 
WT channels (0.5 mM) blocked all three types of channel: by 97.2 ± 0.3% (n = 10) for WT, 
91 ± 2% (n = 6) for hetG334V and 78 ± 2% (n = 7) for homG334V (Fig. 3b). These results 
predict that the individual should be sensitive to sulfonylurea therapy. 
<H1>Discussion 
We report a young woman with a KCNJ11-G334V mutation who, despite being unable to 
stop insulin completely, showed a significant improvement in glycaemic control when high-
dose sulfonylurea therapy was combined with insulin. It is noteworthy that this combination 
therapy also led to a marked improvement in glycaemic variability and in hypoglycaemia 
awareness. Furthermore, mealtime bolus insulin was no longer required. 
The G334V mutation has been described in one previous case, a male, in whom complete 
transfer was also attempted, around 20 years post diagnosis [8]. Despite a rise in C-peptide 
concentration, insulin had to be recommenced after a 5-day trial of glibenclamide. The 
increase in C-peptide demonstrates that β cells were at least partially functional following 
KATP channel closure. Based on our results, it seems possible that the reported case could also 
have been managed on a combination of a low-dose insulin supplemented with sulfonylurea 
treatment. It is important to titrate sulfonylurea doses gradually over time to ascertain 
responsiveness, as demonstrated in our case, where starting doses of glibenclamide had little 
effect on glycaemia. 
In vitro functional studies revealed the G334V mutation led to a small reduction in 
sulfonylurea sensitivity. However, the extent of block (91%) was well within the range 
predicted to enable complete transfer off insulin, based on previous findings (60–75%) [4,6]. 
That our case was unable to do so likely reflects the late age at transfer, because transfer 
success rate declines with duration of diabetes [6,7]. Transfer is unsuccessful in ~ 30% of 
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those over the age of 18, compared with < 5% individuals with the same mutation who are 
aged under 2 years. Rodent models suggest one reason for a better outcome when 
sulfonylurea is commenced early may be that β-cell exposure to chronic hyperglycaemia 
leads to loss of insulin content, impaired β-cell metabolism-secretion coupling and reduced 
β-cell mass [12]. Although it is possible that with further titration of glibenclamide, transition 
off insulin may be achieved, the 3-month trial at higher doses yielded no further reduction in 
insulin. Stopping insulin was characterized by fasting hyperglycaemia and so insulin was 
recommenced. 
Sulfonylurea therapy led to a reduction in glycaemic variability and abolished the 
requirement for mealtime insulin. It is likely that both these effects result from restoration of 
the incretin response. Incretins are only effective when the KATP channels are closed, which 
leads to membrane depolarization, calcium influx and insulin release [13]. Thus, incretin-
based drugs maybe of greater benefit when combined with sulfonylurea therapy. 
It is possible that combination therapy would also be of benefit in people with mutations that 
have shown a reduced blockade in response to tolbutamide. Further studies are needed to 
explore this possibility. 
Two studies have reported treatment outcomes on numbers of individuals with permanent 
neonatal diabetes. Thurber et al. [7] reported that 2 of 57 individuals remained on both 
insulin and sulfonylurea therapy. Babiker et al. [6], defined successful transfer as the ability 
to stop insulin completely. Our study suggests that a reduction in insulin dose should also be 
considered a successful outcome as it is associated with clinical benefits. Indeed, although no 
clinical outcomes were reported, Babiker et al. also recommended trialling combination 
therapy. 
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In conclusion, our data show that in people with KNCJ11 mutations who are unable to 
transfer completely to sulfonylurea therapy, a combination of insulin and sulfonylurea 
treatment may be of clinical benefit, improving glycaemic control, hypoglycaemia awareness 
and glycaemic variability. Furthermore, there may be improvements in quality of life, for 
example, by cessation of insulin pump therapy and managing mealtimes without bolus 
insulin. Thus, the inability to fully transfer off insulin should be still considered a valuable 
treatment in combination with sulfonylureas. 
<H1>Addendum 
While this paper was in review, a paper appeared reporting that two individuals who were 
initially managed solely on sulfonylurea therapy failed to retain good glycaemic control after 
several years, and in these people combination therapy did not produce better glycaemic 
control [14]. This contrasts with our individual who showed an improved outcome and may 
be related to diabetes duration or other factors. 
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FIGURE 1. C-peptide (grey line), insulin (dash line) and glucose (black line) levels during an oral glucose 
tolerance test (OGTT). Glucose was given at time zero. A dose of 5 mg glibenclamide plus 15 units insulin was 
given at t = 150 min with lunch. Note the marked increase in C-peptide after glibenclamide. 
FIGURE 2. Changes in glibenclamide dose (grey line), median blood glucose (black line) and daily basal 
insulin (dashed line) dose during glibenclamide dose titration. Note changes in glycaemia with higher doses of 
glibenclamide not observed at lower doses. 
FIGURE 3. Metabolic sensitivity of the wild-type and mutant KATP channel. (a) Whole-cell currents were 
measured in oocytes expressing wild-type (WT; n = 10), heteromeric (hetG334V; n = 7) or homomeric 
(homG334V; n = 6) KATP channels. The currents were recorded in control solution (black bars), after metabolic 
inhibition with 3 mM sodium azide (white bars) and after the further addition of 0.5 mM tolbutamide (tolb, grey 
bars). (b) Mean ± SEM tolbutamide block for WT (n = 10) and hetG334V (n = 6) channels, compared with the 
mean value for permanent neonatal diabetes mutant channels (n = 19 mutations). Tolbutamide block is 
expressed as the percentage block of the azide-induced current. 
 
Supporting Information 
Additional Supporting Information may be found in the online version of this article: 
Figure S1. The G334V mutation reduces ATP inhibition of the KATP channel. MgATP 
concentration–response relations for wild-type (WT, ), homomeric G334V (homG334V, ) 
and heteromeric (hetG334V, ) KATP channels. The curves are the best fit to the Hill 
equation. 
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Table 1. Clinical and biochemical data before and after commencement of sulphonylurea therapy 
 
 Before After
HbA1c  mmol/mol (%)  88 (10.2) 52 (6.9)
Random C-peptide (pmol/l) f 637 
Paired random glucose (mmol/l) 9.3 6.9 
Total insulin dose in 24 h (units) 80–85 10 
Glibenclamide dose – 40 mg three times daily (2 mg/kg/day) 
Weight (kg) 59 53
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